ATE527998T1 - Illudin-analoga als krebsmittel - Google Patents
Illudin-analoga als krebsmittelInfo
- Publication number
- ATE527998T1 ATE527998T1 AT06800754T AT06800754T ATE527998T1 AT E527998 T1 ATE527998 T1 AT E527998T1 AT 06800754 T AT06800754 T AT 06800754T AT 06800754 T AT06800754 T AT 06800754T AT E527998 T1 ATE527998 T1 AT E527998T1
- Authority
- AT
- Austria
- Prior art keywords
- analogas
- illudin
- cancer medicine
- tumors
- vivo
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title abstract 2
- 229930190064 illudin Natural products 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 230000004614 tumor growth Effects 0.000 abstract 2
- HLAKJNQXUARACO-ZDUSSCGKSA-N (5'r)-5'-hydroxy-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one Chemical class O=C([C@@]1(O)C)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-ZDUSSCGKSA-N 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 abstract 1
- 231100001274 therapeutic index Toxicity 0.000 abstract 1
- 230000004565 tumor cell growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/95—Spiro compounds containing "not free" spiro atoms
- C07C2603/96—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members
- C07C2603/97—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members containing five-membered rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70501705P | 2005-08-03 | 2005-08-03 | |
| PCT/US2006/030439 WO2007019308A2 (en) | 2005-08-03 | 2006-08-03 | Illudin analogs useful as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE527998T1 true ATE527998T1 (de) | 2011-10-15 |
Family
ID=37727922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06800754T ATE527998T1 (de) | 2005-08-03 | 2006-08-03 | Illudin-analoga als krebsmittel |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7655695B2 (de) |
| EP (1) | EP1909783B1 (de) |
| JP (1) | JP4989648B2 (de) |
| AT (1) | ATE527998T1 (de) |
| WO (1) | WO2007019308A2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932553A (en) | 1996-07-18 | 1999-08-03 | The Regents Of The University Of California | Illudin analogs useful as antitumor agents |
| WO2015157578A2 (en) | 2014-04-10 | 2015-10-15 | Af Chemicals, Llc | Affinity medicant conjugates |
| US10285955B2 (en) | 2014-04-10 | 2019-05-14 | Af Chemicals, Llc | Affinity medicant conjugate |
| US11135182B2 (en) | 2014-04-10 | 2021-10-05 | Af Chemicals, Llc | Affinity medicant conjugates |
| CN112804995B (zh) * | 2018-09-04 | 2025-11-04 | 蓝腾制药公司 | 隐杯伞素类似物、其应用及其合成方法 |
| EP3863615A4 (de) * | 2018-10-14 | 2022-08-03 | Lantern Pharma Inc. | Verfahren zur behandlung von krebsen mit soliden tumoren unter verwendung von illudinen und biomarkern |
| EP4524569A3 (de) | 2018-12-11 | 2025-06-18 | AF Chemical LLC | Verfahren, zusammensetzungen und vorrichtungen zur behandlung von krebs mit illudofulvenen |
| US11591295B2 (en) | 2019-11-25 | 2023-02-28 | Af Chemicals Llc | Affinity illudofulvene conjugates |
| US20230181499A1 (en) * | 2020-04-10 | 2023-06-15 | Lantern Pharma Inc. | Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS Cancer |
| WO2021226592A1 (en) * | 2020-05-08 | 2021-11-11 | Lantern Pharma Inc. | Method for treating pancreatic cancer |
| JP2024502001A (ja) | 2020-12-29 | 2024-01-17 | ランタン ファルマ インコーポレイテッド | ラブドイド腫瘍を治療する方法 |
| KR20230130044A (ko) * | 2021-01-08 | 2023-09-11 | 랜턴 파마 인코포레이티드 | 일루딘 또는 하이드록시우레아메틸 아실풀벤을 사용한뇌 전이 및 cns 전이의 치료 |
| AU2022256540A1 (en) * | 2021-04-12 | 2023-11-02 | Lantern Pharma Inc. | Method for treating lung cancer and non-small cell lung cancer |
| CN117320704A (zh) * | 2021-05-03 | 2023-12-29 | 蓝腾制药公司 | 血癌的治疗方法 |
| AU2022317139A1 (en) * | 2021-07-29 | 2024-03-14 | Lantern Pharma Inc. | Treating cancers with combinations of spironolactone and acylfulvenes |
| EP4376822A4 (de) * | 2021-07-29 | 2025-09-17 | Lantern Pharma Inc | Behandlung von krebs mit kombinationen aus parp-inhibitor und acylfulvenen |
| EP4719371A2 (de) * | 2023-05-30 | 2026-04-08 | Lantern Pharma Inc. | Behandlung von krebs mit kombinationen aus anti-cd20-antikörper und acylfulvenen |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US459157A (en) * | 1891-09-08 | Running-gear for vehicles | ||
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4612302A (en) | 1983-11-14 | 1986-09-16 | Brigham And Women's Hospital | Clinical use of somatostatin analogues |
| US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| JPS62234040A (ja) | 1986-04-02 | 1987-10-14 | Kyowa Hakko Kogyo Co Ltd | Ｄｃ１０４３物質 |
| US4853371A (en) | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| DE68913995T2 (de) | 1989-09-27 | 1994-08-25 | Mo Ni Skij I Glaznych Boleznej | Zusammensetzung zur behandlung progressiver myopie. |
| HU208115B (en) | 1989-10-03 | 1993-08-30 | Biochemie Gmbh | New process for producting pleuromutilin derivatives |
| US5439936A (en) | 1989-10-03 | 1995-08-08 | The Regents Of The University Of California | Method of treating certain tumors using illudin analogs |
| EP0565519B1 (de) | 1989-10-03 | 1996-08-28 | The Regents Of The University Of California | Illudin-analoge, verwendet als antitumormittel |
| EP0450761A1 (de) * | 1990-03-02 | 1991-10-09 | Merck & Co. Inc. | Spirocyclische Oxtocin-Antagonisten |
| KR900016822A (ko) * | 1990-04-20 | 1990-11-14 | 하라 레이노스께 | 슬라이드 프로젝터 |
| GB9017024D0 (en) | 1990-08-03 | 1990-09-19 | Erba Carlo Spa | New linker for bioactive agents |
| DZ1773A1 (fr) | 1993-04-27 | 2002-02-17 | Smithkline Beecham Corp | Antagonistes de récepteurs d'endothéline. |
| US5708163A (en) | 1994-03-15 | 1998-01-13 | Sloan-Kettering Institute Of Cancer Research | Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof |
| US6303120B1 (en) | 1994-03-15 | 2001-10-16 | Memorial Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the lewis y epitope and uses thereof |
| WO1996008466A1 (en) * | 1994-09-12 | 1996-03-21 | Takeda Chemical Industries, Ltd. | Benzocycloalkene compounds, their production and use |
| JP3908798B2 (ja) * | 1994-09-12 | 2007-04-25 | 武田薬品工業株式会社 | ベンゾシクロアルケン類、その製造法および剤 |
| US5932553A (en) | 1996-07-18 | 1999-08-03 | The Regents Of The University Of California | Illudin analogs useful as antitumor agents |
| US5723632A (en) | 1996-08-08 | 1998-03-03 | Mgi Pharma, Inc. | Total synthesis of antitumor acylfulvenes |
| US6025328A (en) | 1998-02-20 | 2000-02-15 | The Regents Of The University Of California | Antitumor agents |
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
-
2006
- 2006-08-03 WO PCT/US2006/030439 patent/WO2007019308A2/en not_active Ceased
- 2006-08-03 EP EP06800754A patent/EP1909783B1/de active Active
- 2006-08-03 JP JP2008525225A patent/JP4989648B2/ja active Active
- 2006-08-03 AT AT06800754T patent/ATE527998T1/de not_active IP Right Cessation
- 2006-08-03 US US11/997,432 patent/US7655695B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20080306147A1 (en) | 2008-12-11 |
| US7655695B2 (en) | 2010-02-02 |
| EP1909783A2 (de) | 2008-04-16 |
| WO2007019308A2 (en) | 2007-02-15 |
| EP1909783A4 (de) | 2010-08-04 |
| EP1909783B1 (de) | 2011-10-12 |
| JP4989648B2 (ja) | 2012-08-01 |
| JP2009503110A (ja) | 2009-01-29 |
| WO2007019308A3 (en) | 2007-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE527998T1 (de) | Illudin-analoga als krebsmittel | |
| BRPI0608175A2 (pt) | método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides | |
| IL180725A0 (en) | Inhibitors of angiopoietin-like 4 protein, combinations, and their use | |
| MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
| CL2008003846A1 (es) | Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata. | |
| DK1951729T3 (da) | Oxygenbundne pyrimidinderivater | |
| CU24269B1 (es) | 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante | |
| MX349144B (es) | Supresion de tumores utilizando perfundido placentario humano y celulas destructoras naturales intermediarias derivadas de la placenta humana. | |
| CL2008001745A1 (es) | Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer. | |
| CY1111065T1 (el) | Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| CL2012001180A1 (es) | Compuestos derrivados de pirrolo[2,3-b]piridina; inhibidores de cinasa-fms; metodo de preparacion de los compuestos; composicion y combinacion farmaceutica que los comprende; kit que incluye al compuesto o composicion; y uso en el tratamiento de enfermedades tales como tumores de celulas mamarias, cancer de prostata, alzheimer, entre otras. | |
| PE20070723A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| TW200942552A (en) | Combination therapy with c-Met and HER antagonists | |
| EA201100779A1 (ru) | Композиции антител к cxcr1 и способы их применения | |
| IN2014DN08886A (de) | ||
| GT200600517A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| CL2011000116A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer. | |
| EP1712235A3 (de) | Kombinationstherapy mittels eines niedermolekularen Inhibitors der Interaktion des Oncogens MDM2 mit dem Transkriptionsfaktor P53 | |
| CL2011000119A1 (es) | Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
| CL2011001445A1 (es) | Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias | |
| CY1118073T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης | |
| TW200730532A (en) | Camptothecin derivatives as chemoradiosensitizing agents | |
| WO2021081457A3 (en) | Methods and agents for enhancing t cell therapies | |
| ECSP066458A (es) | 6-[(sustituido)fenil]triazolopirimidinas como agentes anticancer | |
| UY28801A1 (es) | Derivados radiohalogenados de benzamida y su uso en el diagnóstico y la terapia de tumores |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |